Factor IX Inhibition in Thrombosis Prevention (The FIXIT Trial)

NCT00119457 ↗

Phase 2 Completed 300 enrolled vTv Therapeutics

RandomizedParallel-groupDouble-blindPrevention

Summary

The purpose of this study is to determine whether TTP889 prevents venous thromboembolism following surgery to repair hip fracture.

Timeline

Start: 2005-01
Primary completion: —
Completion: 2006-04

Outcome

Missed primary endpoint

paper The primary efficacy outcome occurred in 32.1% (35/109) of patients who had been allocated TTP889, and 28.2% (29/103) of patients on placebo (P = 0.58). PMID 18088349 ↗

Publications

Eriksson BI, Dahl OE, Lassen MR, Ward DP, Rothlein R, Davis G, Turpie AG; Fixit Study Group. Partial factor IXa inhibition with TTP889 for prevention of venous thromboembolism: an exploratory study. J Thromb Haemost. 2008 Mar;6(3):457-63. doi: 10.1111/j.1538-7836.2007.02872.x. Epub 2007 Dec 12.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	TTP889	Small molecule	300 mg	Oral